Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Oruka Therapeutics, Inc.

NASDAQ: ORKA · Life Sciences · 12 alerts · CIK 907654

Share price
$99.24Close, Nov 16
Market cap
$6.73B
Shares outstanding
67.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oruka Therapeutics, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Clinical Trial Data

Oruka Therapeutics Clinical Trial Data

Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met its primary endpoint with 61% of patients in the high-dose (600 mg) group achieving complete skin clearance (PASI 100) compared to 0% for placebo, supporting the planned initiation of Phase 3 trials in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.